Carbonaceous Oral Adsorbent's Effects on Progression of Chronic Kidney Disease
Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
The CAP-KD trial is a prospective, multicenter, randomized, open-label, two-arm, parallel
group comparison clinical trial and will be conducted as a researcher-directed study to
assess the efficacy of Kremezin in preventing the progression of CKD. We compare two groups
of patients: those receiving conventional treatment alone and those receiving such treatment
paired with Kremezin.
Phase:
Phase 4
Details
Lead Sponsor:
Institute for Health Outcomes and Process Evaluation Reseach